Promising Results for Depression Treatment with Microdosing LSD

MindBio Therapeutics Corp. (CSE) has recently unveiled promising durability data from its Phase 2A clinical trials, which tested MB22001, the company’s innovative self-administered, take-home microdose of Lysergic Acid Diethylamide (LSD), as a treatment for depression.

This development underscores MindBio’s commitment to advancing psychedelic medicine as a viable option for mental health treatment.

Read more

Can Microdosing Hurt the Heart?

Psychedelics like psilocybin, MDMA, LSD, and DMT act on serotonin receptors, and previous research has found that other drugs that act on serotonin receptors can cause fibrosis, or the thickening of heart valves.

That, in turn, can lead to serious or even fatal heart issues like arrhythmias or valvular heart disease.

So far, there’s been little research on the link between repeated psychedelics use and heart health, but this week, researchers at the University of Fribourg Center for Psychiatric Research in Switzerland published a paper in the Journal of Psychopharmacology reviewing the existing evidence.

“It is possible that chronic microdosing may carry a risk of fibrosis and valvular heart disease, which should be assessed in future studies,” the authors write.

“Any future work considering longer microdosing regimens should incorporate breaks and regular screening for vascular abnormalities.” 

Microdosing and Authenticity

A recent study found that on the microdosing day and the day thereafter, state authenticity was significantly higher.

Furthermore, the number of activities and the satisfaction with them were higher on the day when participants microdosed, while the following day only the number of activities was higher.

The researchers propose that feeling and behaving authentically could have a central role in explaining the positive effects of microdosing on health and wellbeing that are reported by their study.

Read more

Psilocybin and Lyme Disease?

Psilocybin is both serotonergic and anti-inflammatory and therefore may offer significant therapeutic benefits to patients with mental illness secondary to autoimmune inflammation.

This study suggests that the role of microdosed psilocybin in the treatment of neuropsychiatric Lyme disease and autoimmune encephalopathies warrants further study.

Read more